ADC Programs


FOLR1-directed ADC in preclinical development for ovarian cancer.

IKS012 has been designed to provide a FOLR1-directed therapy with raised TI over in-clinic and on-market competitors - resulting from tumor-selective enzymatic release of an auristatin payload.

In preclinical studies, it is associated with high anti-cancer activity in FOLR1-high xenograft models and class-leading toxicity profile with a HNSTD in non-human primates that is significantly higher than all other FOLR1-directed ADCs.